13F HOLDINGS REPORT
Foresite Capital Management VI LLC
Quarter ended Q1 2025 · Filed May 15, 2025 · Accession 0001104659-25-049404
Total Value
$182.5M
Positions
14
Other Managers
0
Confidential Omitted
No
Holdings (14)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CG Oncology, Inc. | CGON | 2,221,474 | $54.4M | 29.80% |
| 2 | Alumis Inc | ALMS | 4,202,670 | $25.8M | 14.14% |
| 3 | Centessa Pharmaceuticals Inc | CNTA | 1,253,379 | $18.0M | 9.87% |
| 4 | Rapt Therapeutics Inc | 75382E109 | 12,500,000 | $15.3M | 8.35% |
| 5 | Akero Therapeutics Inc | 00973Y108 | 365,000 | $14.8M | 8.09% |
| 6 | Edgewise Therapeutics Inc | EWTX | 585,000 | $12.9M | 7.05% |
| 7 | Bicara Therapeutics Inc | BCAX | 950,000 | $12.4M | 6.78% |
| 8 | Structure Therapeutics Inc | GPCR | 420,000 | $7.3M | 3.98% |
| 9 | Allogene Therapeutics Inc | ALLO | 3,448,275 | $5.0M | 2.76% |
| 10 | Corvus Pharmaceuticals Inc | CRVS | 1,581,233 | $5.0M | 2.75% |
| 11 | Cullinan Therapeutics Inc | CGEM | 634,558 | $4.8M | 2.63% |
| 12 | Kymera Therapeutics Inc | KYMR | 146,332 | $4.0M | 2.19% |
| 13 | Casi Pharmaceuticals Inc | CASIF | 1,329,383 | $2.9M | 1.57% |
| 14 | Viridian Therapeutics, Inc | VRDN | 1,974 | $26,610 | 0.01% |